Shares of Grail (NASDAQ: GRAL) surged by up to 12.4% this week following a rating upgrade from TD Cowen, which shifted its stance from “hold” to “buy.” Despite a price target reduction from $110 to $65, the new target still reflects a 39% upside from Friday’s close, indicating renewed optimism among analysts.
This uptick comes amid a challenging year for Grail, particularly after a disappointing trial outcome for its Galleri test, which failed to meet its primary endpoint of significantly reducing late-stage cancer detections. However, the trial did show promising results in detecting early-stage cancers, suggesting potential for FDA approval and insurance coverage. The analyst upgrade signals a belief that follow-up data could bolster Grail’s efficacy claims and improve market sentiment.
For investors, the key takeaway is that despite recent setbacks, the potential for future data to validate the Galleri test could make Grail an attractive buy at current levels. For a deeper dive into this development, I recommend checking out the full article.
Source: fool.com